GlobeNewswire

PRESS RELEASE: The European Patent Office has granted SSH Communications Security Corporation a further patent for PrivX® technology

Share

The European Patent Office has granted SSH Communications Security Corporation a further patent for PrivX® technology

Helsinki, Finland – January 20, 2021 – The European Patent Office (EPO) has granted SSH patent number EP 3495976 on the use of virtual smart cards in temporary certificate-based passwordless access such as the SSH PrivX technology.

Passwords are a hassle to use, and they present significant security risks for users and organizations of all sizes, with an average of one in every 250 corporate accounts compromised each month. The World Economic Forum (WEF) estimates that cybercrime costs the global economy $2.9 million every minute, with roughly 80 percent of those attacks directed at passwords. Furthermore, password management is very costly: according to the analyst firm Gartner, up to 20 to 50 percent of all help desk calls are for password resets.

The temporary certificate-based access concept used in PrivX removes the need for permanent privileged credentials or passwords altogether, helping customers implement a zero standing privileges (ZSP) strategy through a just-in-time (JIT) model.

The invention enables the extremely high security provided by traditional smart card-based authentication without the associated high cost of issuing plastic smart cards, maintaining them, and exchanging credentials. The invention lets enterprises use the existing and widely adopted smart card access infrastructure for PrivX based access, further lowering the cost and effort of implementing PrivX to provide secure access to critical systems, applications, and data.

PrivX authenticates users just-in-time based on their roles and entitlements and by using certificates that automatically expire after the authentication is complete. The patented innovation does not leave any standing credentials or passwords behind, and the users never handle or see any secrets. This mitigates the risk of privilege abuse, increases productivity, and reduces the complexity of Privileged Access Management.

“We are proud that EPO has further recognized the uniqueness of our PrivX technology and granted this patent,” said Dr. Teemu Tunkelo, CEO of  SSH.COM. “The patent validates the uniqueness of our core design choices of PrivX and gives it a sustainable differentiating edge in next-generation Privileged Access Management (PAM) tools. It also aligns well with recognized industry guidelines like Gartner’s zero standing privileges and just-in-time framework and Zero Trust authentication.”

SSH.COM has an extensive portfolio of patents or patent applications covering all key products and creates shareholder value by giving SSH.COM both the freedom to operate and significant product differentiation.

SSH COMMUNICATIONS SECURITY OYJ

Teemu Tunkelo
CEO

For further information, please contact:
Teemu Tunkelo, CEO, tel. +358 40 5499605

Distribution:
Nasdaq Helsinki Oy
Major media
www.ssh.com

About SSH Communications Security

SSH.COM helps organizations access, secure, and control their digital core – their critical data, applications, and services. We have over 3,000 customers worldwide, including 40 percent of Fortune 500 companies, many of the world's largest financial institutions, and major organizations in all verticals. We are committed to help­ing our customers thrive in the cloud era with solutions that offer secure access with zero inertia, zero friction, and zero credentials risk. SSH.COM sells online; through offices in North America, Europe, and Asia; and a global network of certified partners. The company's shares (SSH1V) are quoted on the NASDAQ Helsinki. For more information, visit www.ssh.com.


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Remuneration of Directors by distribution of Millicom shares8.3.2021 16:50:27 CETPress release

Remuneration of Executives by distribution of Millicom shares Luxembourg, March 8, 2021 – Millicom International Cellular S.A. ("Millicom") announces that, in accordance with the vesting terms and conditions of its deferred share-based compensation plans, approved at Millicom’s 2018, 2019, and 2020 annual general meetings of shareholders, it has distributed treasury shares to eligible plan participants, including 42,833 shares to its executive management team. Details of the distributions are disclosed on Millicom’s website. -END- For further information, please contact: Press: Vivian Kobeh, Corporate Communications Director +1 786 628 5300 press@millicom.comInvestors: Michel Morin, VP Investor Relations +1 786 628 5270 investors@millicom.com Sarah Inmon, Investor Relations Senior Manager +1-786 628 5303 investors@millicom.com About Millicom Millicom (NASDAQ U.S.: TIGO, Nasdaq Stockholm: TIGO_SDB) is a leading provider of fixed and mobile services dedicated to emerging markets in Latin

Synchronoss Announces Appointment of Jeff Miller as Permanent CEO and President8.3.2021 15:21:20 CETPress release

BRIDGEWATER, N.J., March 08, 2021 (GLOBE NEWSWIRE) -- Synchronoss Technologies, Inc. (NASDAQ: SNCR), a global leader and innovator of cloud, messaging and digital solutions, today announced that its Board of Directors has confirmed Jeff Miller as its President and Chief Executive Officer. Miller had been serving as interim President and CEO of Synchronoss since September 2020 and joined Synchronoss in 2018 as Chief Commercial Officer. Prior to coming to Synchronoss, Miller was President of the Technology Group for IDEAL Industries, a firm focused on designing and delivering solutions for smart commercial buildings and spaces. He also served 16 years with Motorola, most recently as Corporate Vice President and General Manager of Operations in North America for Motorola Mobility, LLC, a division of Lenovo. Miller also held various leadership positions in sales management, marketing, and product management at AT&T during an 11-year tenure. “I have had the opportunity to work closely with

AMG Advanced Metallurgical Group N.V. Announces Long-Term Spent Catalyst Recycling Agreement8.3.2021 15:00:00 CETPress release

Amsterdam, 8 March 2021 --- AMG Advanced Metallurgical Group N.V. ("AMG", EURONEXT AMSTERDAM: "AMG") is pleased to announce that AMG Vanadium has signed a new long-term, multi-year agreement to process and recycle spent catalysts from a major oil refinery operator in North America. Located in Cambridge, Ohio, AMG Vanadium specializes in the environmentally beneficial conversion of oil refinery and power plant waste products into specialty metals used by global steel producers in automotive, energy transmission and infrastructure applications. By using materials that would otherwise be discarded as waste, AMG Vanadium facilitates environmental stewardship, energy conservation and resource recovery. About AMG AMG is a global critical materials company at the forefront of CO2 reduction trends. AMG produces highly engineered specialty metals and mineral products and provides related vacuum furnace systems and services to the transportation, infrastructure, energy, and specialty metals & ch

Nexstim Abp offentliggör EU-tillväxtprospekt avseende en företrädesemission på 6,6 miljoner euro8.3.2021 14:15:00 CETPressemelding

Företagsmeddelande, insiderinformation, Helsingfors den 8 mars 2021 kl. 15.15 (EET) Nexstim Abp offentliggör EU-tillväxtprospekt avseende en företrädesemission på 6,6 miljoner euro Nexstim Abp (NXTMH:HEX, NXTMS:STO) (”Nexstim” eller ”bolag”) meddelar med hänvisning till bolagets företagsmeddelande utgiven tidigare i dag, om en företrädesemission av cirka 6,6 miljoner euro att bolaget har upprättat ett EU-tillväxtprospekt som Finansinspektionen godkände den 8 mars 2021. Bolagets styrelse beslutade att offentliggöra EU-tillväxt prospektet den 8 mars 2021 och det ska notifieras till Sverige. EU-tillväxtprospektet på finska läggs omkring den 8 mars 2021 ut på Nexstims webbplats på www.nexstim.com/investors/rights-issue-2021 och tillhandahålls också på bolagets registrerade adress på Elimäkigatan 9 B, 00510 Helsingfors. Dessutom görs EU-tillväxtprospektet på finska tillgängligt på receptionen på Nasdaq Helsinki på Fabiansgatan 14, 00100 Helsingfors. EU-tillväxtprospektet på engelska och en

Nexstim Plc publishes an EU growth prospectus regarding EUR 6.6 million subscription rights issue8.3.2021 14:15:00 CETPress release

Company announcement, inside information, Helsinki, 8 March 2021 at 3.15 PM (EET) Nexstim Plc publishes an EU growth prospectus regarding EUR 6.6 million subscription rights issue Nexstim Plc (NXTMH:HEX, NXTMS:STO) (”Nexstim” or ”Company”) announces with reference to the company announcement published earlier today regarding a subscription rights issue totaling approximately EUR 6.6 million , that the Company has prepared an EU growth prospectus which the Finnish Financial Supervisory Authority (FIN-FSA) has approved on 8 March 2021. The Board of Directors of Nexstim has resolved to publish the EU growth prospectus on 8 March 2021 and it shall be notified to Sweden. Finnish version of the EU growth Prospectus will be available approximately on 8 March 2021 on the Nexstim’s website at http://www.nexstim.com/investors/rights-issue-2021 and at the registered office of the Company at Elimäenkatu 9 B, 00510 Helsinki. Moreover, the Finnish version of the EU growth prospectus will be availabl

Saniona får återkoppling från FDA gällande den regulatoriska vägen framåt för Tesomet mot hypotalamisk fetma8.3.2021 14:00:00 CETPressemelding

PRESSMEDDELANDE 8 mars 2021 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, meddelar idag att det amerikanska läkemedelsverket FDA lämnat återkoppling som ytterligare klarlägger det regulatoriska spåret för Tesomet som behandling av hypotalamisk fetma (HO). Baserat på den erhållna återkopplingen går Saniona vidare med planerna att inleda en fas 2b-studie på HO under första halvåret innevarande år. ”I dagsläget finns inga godkända mediciner för hypotalamisk fetma, en sällsynt sjukdom sekundär till skador i hypotalamus. Sjukdomen kännetecknas av svårhanterlig viktuppgång och kompliceras av okontrollerbar hunger”, säger Rudolf Baumgartner, Sanionas Chief Medical Officer och Head of Clinical Development. ”Återkopplingen från FDA är uppmuntrande, och vi ser fram emot att fortsätta den konstruktiva dialogen med myndigheten medan vi förbereder starten av vår kliniska fas 2b-studie med Tesomet.” Som Saniona tidigare meddelat har FDA

Saniona Receives Feedback from U.S. FDA Providing a Regulatory Path Forward for Tesomet in Hypothalamic Obesity8.3.2021 14:00:00 CETPress release

PRESS RELEASE March 8, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced it received feedback from the U.S. Food and Drug Administration (FDA) providing further clarity on a regulatory path for Tesomet in the treatment of hypothalamic obesity (HO). Based on this feedback, Saniona is proceeding with plans to initiate a Phase 2b study in HO in the first half of this year. “There is currently no medicine approved for hypothalamic obesity, a rare disease secondary to hypothalamic injury, characterized by intractable weight gain and complicated by uncontrollable hunger,” said Rudolf Baumgartner, M.D., Chief Medical Officer and Head of Clinical Development at Saniona. “We are encouraged by this feedback from the FDA and look forward to continuing a constructive dialogue with them as we prepare to initiate our Phase 2b clinical trial with Tesomet.” Saniona previously announced that the FDA had highlighted the potential for off-lab